Search
Close this search box.

Oncological diagnosis

TECHNOLOGY IN THE SERVICE OF HEALTH

Our fight for early cancer detection

For more than a decade, Life Length has been conducting research on the efficacy of telomeres as predictive and prognostic markers for oncological diseases.

TELOMERES AND CANCER

Oncologic diagnosis involves understanding the differences between tumor cells and normal cells. As a cell becomes tumorous, its telomeres shorten and, in a large proportion of cases, telomerase is activated. The telomeres of tumor cells are usually shorter than those of normal somatic cells, and approximately 90% of them exhibit high telomerase activity.

When the telomeres of tumor cells become critically shortened or dysfunctional, these cells become genetically unstable, which is often correlated with increased tumor aggressiveness. Instead of undergoing senescence or cell death, cancer cells acquire immortality and the ability to replicate indefinitely, even with short telomeres.

The combination of telomeric shortening with oncogenic changes allows tumor cells to avoid senescence and become immortal, usually through activation or positive regulation of telomerase, which drives malignant transformation and uncontrolled tumor growth.

Therefore, alterations in telomeric length are a crucial biomarker in cancer. This relationship has been widely shown in more than 7,000 peer-reviewed scientific and clinical publications.

Since telomere lengths in different somatic tissues are highly correlated, telomere length in leukocytes is considered a reliable surrogate measure of telomere length in the tissues of interest.

ONCOCHECK is a set of clinical studies conducted by Life Length between 2017 and 2022 with funding granted by the European Union Horizon 2020 research and innovation programme.

The objective of the ONCOCHECK project was the clinical validation of telomere-associated variables (TAVs) as oncological biomarkers by managing and analysing massive amounts of data with the aim of generating algorithms to improve cancer management.

The ONCOCHECK project made it possible to analyse TAVs in a wide variety of cancers including solid tumours, leukaemia, and childhood tumours, among others.

Recruited patients
0
Hospitals involved
0

The new biomarker through telomere detection in early diagnosis of prostate cancer.

We present a new specific tool for the early diagnosis of prostate cancer (PCa) in patients with PSA levels between 3 and 10 ng/ml, allowing for risk stratification of this type of cancer. It also reduces the number of necessary biopsies by one-third . Thus, it decreases direct healthcare costs and provides a simpler, faster, and more comfortable procedure for patients. Our telomere measurement technology brings significant innovation to diagnostic procedures.

Our biomarker received the AEMPS (Spanish Agency for Medicines and Health Products) approval for use within the EU (CE IVD)

RESEARCH FOR A NEW BIOMARKER BY TELOMERIC DETECTION IN THE DIAGNOSIS OF LUNG CANCER

In 2023 we were distinguished with a grant from the Community of Madrid after obtaining the Seal of Excellence within the prestigious European Innovation Council Accelerator program, for research into the early diagnosis of lung cancer. This grant, aimed at boosting our research, marks a significant step towards the development of a non-invasive, clinically effective and highly accurate test for the early detection of lung cancer. One of our main objectives is to bring to market an early detection tool for lung cancer to improve the quality of life of patients and reduce associated complications.

  1. Rubio Galisteo, J.M., Fernández, L., Gómez Gómez, E. et al. Telomere-based risk models for the early diagnosis of clinically significant prostate cancer. Prostate Cancer Prostatic Dis 24, 88–95 (2021). https://doi.org/10.1038/s41391-020-0232-4
  2. de Pedro, N., Díez, M., García, I. et al. Analytical Validation of Telomere Analysis Technology® for the High-Throughput Analysis of Multiple Telomere-Associated Variables. Biol Proced Online 22, 2 (2020). https://doi.org/10.1186/s12575-019-0115-z
Do you want to know more?
Contact us

DO YOU WANT MORE INFORMATION?

For further information or enquiries please contact info@lifelength.com or leave your details on this form.

DO YOU WANT MORE INFORMATION?

For further information or enquiries please contact oncologydiagnostics@lifelength.com or leave your details on this form.

We inform our valued customer community that we have made the difficult decision to close our General Martinez Campos clinic.

However, we want to assure our customers that Life Length will continue to provide its proprietary telomere measurement services and HealthTAV®, HealthOX and HealthNAD+ assays in more than 35 countries. We will also continue to work closely with physicians and clinics committed to personalised medicine, longevity and healthy ageing.

It is a true privilege and honour to have had the opportunity to serve and assist tens of thousands of clients who have placed their trust in our clinic since the beginning of the pandemic. We express our deepest appreciation.

If you have any questions or queries, please do not hesitate to write to us at info@lifelength.com. We are here to help you in any way we can.

Be part of our team

For further information or enquiries, please leave your details on this form.

DO YOU WANT MORE INFORMATION?

For further information or enquiries please contact clinica@lifelength.com or leave your details on this form.

Our tests

DO YOU WANT MORE INFORMATION?

For further information or enquiries please contact contractresearch@lifelength.com or leave your details on this form.